Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with aflibercept, dexamethasone intravitreal implant and ranibizumab under the National Health Act 1953, section 85 for patients with BRVO or CRVO with macular oedema.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing aflibercept, dexamethasone intravitreal implant and ranibizumab.
Treatment specifics
To be eligible for PBS-subsidised treatment with these medications, patients must be treated by:
- an ophthalmologist
- an accredited ophthalmology registrar in consultation with an ophthalmologist.
Authority applications
Applying for initial treatment
Applications for initial authority approval to prescribe PBS-subsidised aflibercept, dexamethasone intravitreal implant and ranibizumab to treat BRVO or CRVO can be made either in:
- real time using the Online PBS Authorities system
- writing and use HPOS Form upload
- writing and mail to PBS Complex Drugs Programs.
All written applications must include the completed:
- authority prescription form or forms
- retinal vein occlusion - initial authority application form
- relevant attachments.
Applications to move between different drugs to treat BRVO or CRVO will require a new initial authority application to be completed.
Applying for continuing treatment
Continuing PBS-subsidised treatment with aflibercept, dexamethasone intravitreal implant and ranibizumab is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.